Company profile: Chase Therapeutics
1.1 - Company Overview
Company description
- Provider of early-stage, product-based specialty pharmaceuticals, including CTC-413 for symptomatic and neuroprotective treatment of Parkinson’s disease and related disorders (Phase 2), CTC-501 for symptomatic treatment of major depressive disorder (Phase 2), and a Parkinson’s disease bioassay for diagnosis and immediate-response outcome measurement in clinical trials.
Products and services
- CTC-413: A clinical-stage compound delivering symptomatic relief and neuroprotective effects for Parkinson’s disease and related disorders, currently advancing through Phase 2 clinical evaluation
- Bioassay for Parkinson’s Disease: An under-development diagnostic tool engineered to diagnose Parkinson’s disease and related disorders and serve as an immediate response outcome measure in clinical trials
- CTC-501: A clinical-stage compound producing symptomatic treatment benefits for major depressive disorder, currently in Phase 2 clinical evaluation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Chase Therapeutics
Link Medicine
HQ: United States
Website
- Description: Provider of research aimed at creating disease-modifying therapies for neurodegenerative diseases, including Alzheimer's and Parkinson's disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Link Medicine company profile →
Vect-Horus
HQ: France
Website
- Description: Provider of peptide-based vectors and the VECTrans technology platform enabling targeted delivery of therapeutic molecules and imaging agents across biological barriers, including the blood-brain barrier, organs, and tumors, by targeting receptors involved in receptor-mediated transport (RMT). Services include vector discovery/optimization, in vitro/in vivo evaluation, internal pipeline development, and R&D, licensing, and strategic partnerships.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vect-Horus company profile →
Neurelis
HQ: United States
Website
- Description: Provider of specialty pharmaceutical therapies addressing unmet medical needs, including VALTOCO, a prescription nasal spray for short-term treatment of seizure clusters in patients aged 6 and older; and pipeline programs NRL-1004 for acute agitation using proprietary Intravail delivery technology, and NRL-1049 for cerebral cavernous malformations, potentially the first FDA-approved treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neurelis company profile →
Convelo Therapeutics
HQ: United States
Website
- Description: Provider of novel remyelinating therapeutics that regenerate myelin in the central nervous system to restore function, supported by a proprietary screening platform that identifies candidates acting on oligodendrocyte progenitor cells, and a collaboration with Genentech to accelerate discovery and development of medicines for neurological disorders such as multiple sclerosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Convelo Therapeutics company profile →
Pacira BioSciences
HQ: United States
Website
- Description: Provider of specialty pharmaceutical products and pain management technologies, including EXPAREL, a local anesthetic used during surgery to manage pain and reduce opioid use; ZILRETTA, an extended-release injectable for osteoarthritis knee pain; ioveraº, a cryoanalgesia system delivering immediate relief; and pMVL, a multivesicular liposome drug delivery technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pacira BioSciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Chase Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Chase Therapeutics
2.2 - Growth funds investing in similar companies to Chase Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Chase Therapeutics
4.2 - Public trading comparable groups for Chase Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →